A study to investigate the effect of AZD0780 on metformin pharmacokinetics in healthy adult volunteers aged 18 to 55 years

Inclusion Criteria

• Inclusion Criteria:
• - Have a body mass index (BMI) between 18 and 35 kilograms per meter squared (kg/m2) inclusive and weigh at least 50 kilograms (kg) at the Screening Visit.
• - Participants agree to follow study specific contraceptive requirements.
• - Have suitable veins for cannulation or repeated venipuncture.
• Exclusion Criteria:
• - History of any clinically important disease or disorder which may put the participant at risk because of participation in the study or influence the results.
• - Any positive result on Screening for serum hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), hepatitis C antibody (HCVAb), or human immunodeficiency virus (HIV).
• - Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of study intervention.
• - History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity, or history of hypersensitivity to drugs with a similar chemical structure or class to metformin or AZD0780.
• - Treatment with any lipid lowering therapy or AZD0780 within the 3 months prior to the Screening Visit.
• - Treatment with drugs for reduction or inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) within the last 12 months prior to the Screening Visit (approved or investigational and apart from AZD0780).
• - Current or previous administration of inclisiran.